Viloxazine occupies the 5-HT2C receptor in the macaca fascicularis brain in vivo: A [11C]CIMBI-36 positron emission tomography study

Efficacy of viloxazine ER (extended-release capsules; Qelbree®) for attention-deficit/hyperactivity disorder (ADHD) is attributed to its ability to increase extracellular norepinephrine and dopamine in the medial prefrontal cortex by inhibiting norepinephrine transporters (NET); however, studies also suggest potentially relevant activity at serotonin (5-HT) receptors. This positron emission tomography (PET) study in macaca fascicularis monkeys measured viloxazine binding to 5-HT2C/5-HT2A…

via https://pubmed.ncbi.nlm.nih.gov/42335010/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260703010905&v=2.20.0